Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Obesity, Cardiac MRI Structure and Non-ischaemic Cardiomyopathy
Author(s): Long Peng , Tao Zeng , Enxi Quan , et al Added: 1 month ago

Cardiovascular Renal Metabolic

Heart Failure
ESC HF 25: CRISPR in ATTR-CM: Hereditary vs Wild-Type
Author(s): Marianna Fontana Added: 1 month ago
ESC HF 25 - A study investigating CRISPR gene editing with nexiguran ziclumeran in ATTR cardiomyopathy demonstrated favourable safety and tolerability, with consistent reductions in serum TTR in both wild-type and variant disease.Prof Marianna Fontana (University College London, UK) joins us to discuss the key findings from a two-part, open-label, phase 1 study investigating the treatment effect,… View more

Heart Failure
Potential Reversibility of ATTR-CM through Anti-ATTR Amyloid Antibodies
Author(s): Marianna Fontana Added: 1 year ago
Prof Marianna Fontana (University College London, UK) joined us to discuss the discovery and impact of antibody-associated reversal of ATTR amyloidosis–related cardiomyopathy in three patients. Prof Fontana and her team, in a correspondence published in The New England Journal of Medicine, revealed the identification of an antibody linked to the spontaneous reversal of cardiac transthyretin… View more

Heart Failure
ESC 23: ATTRibute-CM Trial
Author(s): Julian Gillmore Added: 1 year ago
ESC 2023 — Prof Julian Gillmore (University College London, UK) joins us onsite to discuss the findings of the ATTRibute-CM Study (NCT03860935). ATTRibute-CM was a randomised double-blind trial which aimed to evaluate the safety and efficacy of acoramidis in a cohort of patients diagnosed with transtherytin amyloid cardiomyopathy (ATTR-CM). 632 patients were enrolled in the trial, and were… View more

Heart Failure
AHA 24: Nexiguran Ziclumeran for ATTR-CM
Author(s): Marianna Fontana Added: 6 months ago
AHA Conference 2024 - Safety and efficacy outcomes of nexiguran ziclumeran (NTLA-2001) in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM).Dr Marianna Fontana (University College London, London, UK) joins us onsite at AHA Conference to discuss the findings from the nexiguran ziclumeran for ATTR-CM trial (NCT04601051).Dr Fontana discusses a phase 1, ongoing, open-label, single… View more

Heart Failure
Author(s): Julian Gillmore , Margot K Davis , Ahmad Masri , et al Added: 9 months ago
First presented at ESC 2024, this on-demand programme sees Prof Julian Gillmore (University College London, London, UK) lead a distinguished faculty compromising of Dr Ahmad Masri (Oregon Health & Science University Medical Group, Portland, US), Dr Margot Davis (University of British Columbia, Vancouver, CA), and Dr Giuseppe Vergaro (Sant’Anna, Pisa, IT).The faculty present recent epidemiological… View more

Heart Failure
NHC On Demand Thumbnail
Author(s): Perry Elliott , Marianna Fontana , Ahmad Masri , et al Added: 3 months ago
Radcliffe Cardiologywas proud to hostNew Horizons in Cardiomyopathy 2025 (NHC), specially focused on cardiac amyloidosis and cardiomyopathy diagnosis and treatment.Day 1 focused on hypertrophic cardiomyopathy (HCM), with a detailed exploration of HCM and an emphasis on emerging therapies and management strategies. Day 2 focused on amyloidosis, providing a comprehensive update on the diagnosis and… View more

Heart Failure
Research Area(s) / Expertise:
Prof Ewa Jankowska is Professor of Medicine and Head of Laboratory of Applied Research on Cardiovascular System at the Department of Heart Diseases, Wroclaw Medical University, Poland. Her clinical and research interests include the role of peripheral mechanisms in the progression of heart failure, co-morbidities in heart failure, and experimental model of tachycardia-induced cardiomyopathy. … View more
AHA 23: Screening for Peripartum Cardiomyopathies Using an AI Enanced Digital Stethoscope
Author(s): Demilade Adedinsewo Added: 1 year ago
AHA 23 - We are joined by Dr Demilade Adedinsewo (Mayo Clinic, US) to discuss the findings from a study investigating the effectiveness of an artificial intelligence-enabled ECG (AI-ECG) for cardiomyopathy detection in an obstetric population.In the intervention arm, the digital stethoscope correctly identified 92% of those with ejection fraction <50% and 100% of those with ejection fraction … View more

Demographic

Heart Failure